These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 426401)

  • 1. Spironolactone-induced hyperchloremic acidosis in cirrhosis.
    Gabow PA; Moore S; Schrier RW
    Ann Intern Med; 1979 Mar; 90(3):338-40. PubMed ID: 426401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholestyramine induced hyperchloremic metabolic acidosis.
    Eaves ER; Korman MG
    Aust N Z J Med; 1984 Oct; 14(5):670-2. PubMed ID: 6597713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites.
    Campra JL; Reynolds TB
    Am J Dig Dis; 1978 Nov; 23(11):1025-30. PubMed ID: 31086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperchloremic metabolic acidosis with high serum potassium in renal transplant recipients: a cyclosporine A associated side effect.
    Stahl RA; Kanz L; Maier B; Schollmeyer P
    Clin Nephrol; 1986 May; 25(5):245-8. PubMed ID: 3521998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acidosis and extreme hyperkalemia associated with cholestyramine and spironolactone.
    Zapater P; Alba D
    Ann Pharmacother; 1995 Feb; 29(2):199-200. PubMed ID: 7756724
    [No Abstract]   [Full Text] [Related]  

  • 6. Spironolactone and enzyme induction in patients with alcoholic cirrhosis.
    Miguet JP; Vuitton D; Thebault-Lucas A; Joanne C; Dhumeaux D
    Gastroenterology; 1980 May; 78(5 Pt 1):996-1000. PubMed ID: 7380205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Captopril-induced metabolic acidosis with hyperkalemia.
    Sakemi T; Ohchi N; Sanai T; Rikitake O; Maeda T
    Am J Nephrol; 1988; 8(3):245-8. PubMed ID: 3071139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients.
    Ramsay LE; Hettiarachchi J; Fraser R; Morton JJ
    Clin Pharmacol Ther; 1980 Apr; 27(4):533-43. PubMed ID: 7357812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.
    Papadopoulos N; Vasiliki A; Aloizos G; Tapinis P; Kikilas A
    Ann Pharmacother; 2010 Jan; 44(1):219-21. PubMed ID: 19934389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholestyramine-induced hyperchloremic metabolic acidosis.
    Scheel PJ; Whelton A; Rossiter K; Watson A
    J Clin Pharmacol; 1992 Jun; 32(6):536-8. PubMed ID: 1634640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of chronic hypotonic volume expansion on the renal regulation of acid-base equilibrium.
    Lowance DC; Garfinkel HB; Mattern WD; Schwartz WB
    J Clin Invest; 1972 Nov; 51(11):2928-40. PubMed ID: 5080418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment.
    Feinfeld DA; Carvounis CP
    JAMA; 1978 Sep; 240(14):1516. PubMed ID: 682358
    [No Abstract]   [Full Text] [Related]  

  • 14. NaHCO3 therapy corrects the increased urinary Na, K, Cl and H2O excretion induced by NH4Cl.
    Cogan MG; Mueller MR
    Miner Electrolyte Metab; 1983; 9(3):132-6. PubMed ID: 6308411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone and metabolic acidosis.
    Nierenberg DW
    Ann Intern Med; 1979 Aug; 91(2):321-2. PubMed ID: 464487
    [No Abstract]   [Full Text] [Related]  

  • 16. Metolazone and spironolactone in cirrhosis and the nephrotic syndrome.
    Lang GR; Westenfelder C; Nascimento L; Dhupelia VB; Arruda JA; Kane RE
    Clin Pharmacol Ther; 1977 Feb; 21(2):234-43. PubMed ID: 319937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal "anion gap" (hyperchloremic) acidosis.
    Walmsley RN; White GH
    Clin Chem; 1985 Feb; 31(2):309-13. PubMed ID: 3967372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperchloremic acidosis during the recovery phase of diabetic ketosis.
    Oh MS; Carroll HJ; Goldstein DA; Fein IA
    Ann Intern Med; 1978 Dec; 89(6):925-7. PubMed ID: 102229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interest of the association clonidine-spironolactone in cirrhotic patients with ascites and activation of sympathetic nervous system.
    Lenaerts A; Codden T; Van Cauter J; Meunier JC; Henry JP; Ligny G
    Acta Gastroenterol Belg; 2002; 65(1):1-5. PubMed ID: 12014310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of extracellular fluid volume depletion on renal regulation of acid-base and potassium equilibrium during prolonged mineral acid administration.
    Hulter HN; Toto RD; Sebastian A; Mackie S; Cooke CR; Wilson TE; Melby JC
    J Lab Clin Med; 1984 Jun; 103(6):854-68. PubMed ID: 6726056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.